 VANCOUVER, Washington, June 16, 2021 GLOBE NEWSWIRE -- CytoDyn Inc. OTCQB: CYDY, CytoDyn or the Company, a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Chief Operating Officer and Head of Clinical Development, will host an investment community webcast on Monday, June 21, 2021. 